Abstract
Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification.
In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.Keywords: Hypertension, aortic valve stenosis, antihypertensive drugs, ACEi/ARB, diuretics, alpa- beta-blockers, calcium channel blockers, vasodilators.
Current Pharmaceutical Design
Title:Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Volume: 23 Issue: 8
Author(s): Paolo Poggio*, Gianluca Folesani, Giuseppe M. Raffa, Paola Songia, Vincenzo Valenti, Veronika Myasoedova and Alessandro Parolari
Affiliation:
- Laboratory of Biochemical Cardiology Unit for the Study of Aortic, Valvular and Coronary Pathologies Centro Cardiologico Monzino, IRCCS Via Carlo Parea 4, 20138 Milan,Italy
Keywords: Hypertension, aortic valve stenosis, antihypertensive drugs, ACEi/ARB, diuretics, alpa- beta-blockers, calcium channel blockers, vasodilators.
Abstract: Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification.
In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.Export Options
About this article
Cite this article as:
Poggio Paolo*, Folesani Gianluca, Raffa M. Giuseppe, Songia Paola, Valenti Vincenzo, Myasoedova Veronika and Parolari Alessandro, Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis, Current Pharmaceutical Design 2017; 23 (8) . https://dx.doi.org/10.2174/1381612823666161123144534
DOI https://dx.doi.org/10.2174/1381612823666161123144534 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms
CNS & Neurological Disorders - Drug Targets The Relationship Between Prolidase Activity and Atrial Electromechanical Changes in Patients with Paroxysmal Atrial Fibrillation
Combinatorial Chemistry & High Throughput Screening Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors
Medicinal Chemistry Quantitative Analysis in Cardiovascular Imaging: Current Status
Current Medical Imaging Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Barriers to Risk Stratification Accuracy in Ischemic Heart Disease in Women: The Role of Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design High Throughput Metabolomics in Clinical Studies: Review and New Applications to Remote Ischemic Preconditioning
Current Topics in Medicinal Chemistry The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options
Current Cardiology Reviews Animal Models to Study Plaque Vulnerability
Current Pharmaceutical Design Predictive Genomics DNA Profiling for Athletic Performance
Recent Patents on DNA & Gene Sequences A Multidisciplinary Atrial Fibrillation Clinic
Current Cardiology Reviews Headache, Outpatient Management and Referral to Specialty Clinics, Clinical Audit
New Emirates Medical Journal Mechanisms of Vascular Hyporesponsiveness in Septic Shock
Current Vascular Pharmacology Platelet Ca2+ATPases: Identification and Regulation in Hypertension
Current Hypertension Reviews Common Drugs for Stabilization of Renal Function in the Progression of Diabetic Nephropathy and Their Relations with Hypertension Therapy
Current Diabetes Reviews Clinical and Pre-clinical Applications of the Transcendental Meditation Program® in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults
Current Hypertension Reviews Recent Advance in the Pharmacology of Dihydropyrimidinone
Mini-Reviews in Medicinal Chemistry L-Arginine Signalling Potential in the Brain: The Peripheral Gets Central
Recent Patents on CNS Drug Discovery (Discontinued) Cardiovascular Disease in the Systemic Vasculitides
Current Vascular Pharmacology The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology